Thimerosal News and Research

RSS

CRISPR/Cas9-based screening identifies potential therapies for non-alcoholic fatty liver disease

Activation of the NRF2 transcription factor shows promise as a potential treatment approach for non-alcoholic fatty liver disease (NAFLD), a condition associated with oxidative stress and liver damage. By screening FDA-approved drugs, researchers identified six compounds that enhanced NRF2 activity and demonstrated protective effects against oxidative stress and lipid accumulation.

3 Jul 2023

Auranofin inhibits SARS-CoV-2 replication

In a new ISCIENCE journal study, scientists identified an FDA-approved NF-κB inhibitor, Auranofin, which can also control inflammation.

6 Sep 2022

Protein Sciences, UNIGEN agree to supply Flublok influenza vaccine for the U.S. market from Japan

Protein Sciences Corporation (Meriden, CT and Pearl River, NY) and UMN Pharma Inc. (Akita, Akita prefecture, Japan) announced today that Protein Sciences and UNIGEN Inc., a joint venture of UMN and IHI Corporation (Koto-ku, Tokyo, Japan), entered into an agreement to source bulk Flublok influenza vaccine from Japan for the U.S. market.

12 Feb 2016

President and CEO of Protein Sciences elected as 2015 Fellow of the International Society for Vaccines

Protein Sciences Corporation, the makers of Flublok Influenza Vaccine, announced today that Dr. Manon Cox, President and CEO, was elected as a 2015 Fellow of the International Society for Vaccines (ISV). The ISV is an esteemed organization dedicated to the development, advancement and use of vaccines to prevent and control disease.

30 Oct 2015

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.

3 Jun 2015

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology.

13 May 2015

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences Corporation, along with The Connecticut Association for Healthcare at Home, announced a new partnership today that will bring Flublok influenza vaccine to home health and hospice agencies across the state. As a new affinity partner of CTH@H, Protein Sciences will make Flublok available to CTH@H member agencies for the 2015/16 flu season.

5 May 2015

Protein Sciences earns Frost & Sullivan 2013 Global New Product Innovation Award

Based on its recent analysis of the influenza vaccines market, Frost & Sullivan recognises Protein Sciences with the 2013 Global New Product Innovation Award. Flublok is the world's first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

29 Dec 2014

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment.

29 Sep 2014

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok.

9 Jul 2014

Astellas seeks marketing approval for Flublok recombinant influenza vaccine in Japan

Protein Sciences Corporation announced today that Astellas Pharma has submitted an application for marketing approval of recombinant influenza HA vaccine ASP7374 (marketed as Flublok® in the United States by Protein Sciences) to the Ministry of Health, Labour and Welfare in Japan for the prevention of influenza.

31 May 2014

Flublok influenza vaccine for the 2013-14 season now available

Protein Sciences Corporation, the manufacturer of Flublok, the new, pure influenza vaccine containing no egg proteins, influenza virus, preservatives (e.g., thimerosal), antibiotics, gelatin or latex, announced today that doses for the 2013-14 season have been released by the FDA and are now available.

14 Nov 2013

Unique mobile app allows parents to access information about safety of vaccines

The Vaccine Education Center at The Children's Hospital of Philadelphia is launching Vaccines on the Go: What You Should Know, a unique mobile app that allows busy parents to access up-to-date, reliable information about the science and safety of vaccines -- wherever and whenever they need it.

11 Sep 2013

First lots of 2013-2014 seasonal influenza vaccine released for U.S. distribution

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration for U.S. distribution and were shipped July 24.

25 Jul 2013

FDA approves Protein Sciences’ Flublok to prevent seasonal influenza

The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.

18 Jan 2013

Experts question proposed mercury preservative ban in vaccines

A ban on the use of a mercury-based preservative in vaccines tabled by the United Nations Environmental Program should be struck from a draft treaty as it may severely affect access to vaccines, experts urge.

4 Jan 2013

Banning thimerosal from vaccines could hinder achievements in global childhood immunization

"Thanks to a herculean effort by health advocates, 78 percent of children in low-income countries receive the basic set of childhood vaccines, covering diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenza," a Bloomberg View editorial states.

3 Jan 2013

Experts warn banning thimerosal from use in vaccines would harm immunization campaigns in developing world

"A group of prominent doctors and public health experts warns in articles to be published Monday in the journal Pediatrics that banning thimerosal, a mercury compound used as a preservative in vaccines, would devastate public health efforts in developing countries," the New York Times reports.

17 Dec 2012

First Edition: December 17, 2012

Today's headlines include weekend updates regarding the fiscal cliff negotiations as well as news regarding states' decisions on health exchanges.